Evidence map›Paper›PMID 34407480›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2021

Cross-reactive humoral immune responses against seasonal human coronaviruses in COVID-19 patients with different disease severities.

Kazuo Imai, Masaru Matsuoka, Sakiko Tabata, Yutaro Kitagawa, Mayu Nagura-Ikeda, Katsumi Kubota, Ai Fukada, Tomohito Takada, Momoko Sato, Sakiko Noguchi and 5 more

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cohort profile:BMJ open · 2022
    Article
  8. Review
  9. Review
  10. Long-Term, CD4Frontiers in immunology · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Kazuo ImaiDepartment of Infectious Disease and Infection Control, Saitama Medical University, Saitama, Japan; Self-Defense Forces Central Hospital, Tokyo, Japan. Electronic address: k_imai@saitama-med.ac.jp.
Masaru MatsuokaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Sakiko TabataSelf-Defense Forces Central Hospital, Tokyo, Japan.
Yutaro KitagawaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Mayu Nagura-IkedaSelf-Defense Forces Central Hospital, Tokyo, Japan.
Katsumi KubotaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Ai FukadaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Tomohito TakadaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Momoko SatoDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Sakiko NoguchiDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Shinichi TakeuchiDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Noriaki ArakawaDivision of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki City, Kanagawa, Japan.
Kazuyasu MiyoshiSelf-Defense Forces Central Hospital, Tokyo, Japan.
Yoshiro SaitoDivision of Medicinal Safety Science, National Institute of Health Sciences, Kawasaki City, Kanagawa, Japan.
Takuya MaedaDepartment of Clinical Laboratory, Saitama Medical University Hospital, Saitama, Japan.
Saitama Medical University Hospital · JPSelf-Defense Forces Central Hospital · JPNational Institute of Health Sciences · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe cross-reactive antibody response against seasonal human coronaviruses (HCoVs) was evaluated according to disease severity in patients with COVID-19 in Japan.

methodsIn total, 194 paired serum samples collected from 97 patients with COVID-19 (mild, 35; severe, 62) were analyzed on admission and during convalescence. IgG antibodies against the nucleocapsid (N) and spike (S) proteins of SARS-CoV-2 and four seasonal HCoVs (HCoV-NL63, -229E, -OC43, and -HKU1) were detected by enzyme-linked immunosorbent assays.

resultsThere was no difference in optical density (OD) values for seasonal HCoVs on admission between the severe and mild cases. In addition, a specific pattern of disease severity-associated OD values for HCoVs was not identified. Significant increases in OD values from admission to convalescence for HCoV-HKU1and -OC43 IgG-S, and for HCoV-NL63 and -229E IgG-N were observed in the severe cases. Significant differences were observed between the mild and severe cases for HCoV-HKU1 and -OC43 IgG-S OD values during convalescence. Correlations were found between the fold changes for HCoV-OC43 IgG-S OD values, and for SARS-CoV-2 IgG-S OD values, and C-reactive protein, lactate dehydrogenase, and lymphocyte levels.

conclusionThere was no association between the antibody titer for seasonal HCoVs in the early phase of COVID-19 and disease severity.

Indexed as

COVID-19HumansImmunity, HumoralSARS-CoV-2SeasonsSeverity of Illness IndexSpike Glycoprotein, CoronavirusSpike Glycoprotein, CoronavirusantibodyCOVID-19cross-reactivityJapanSARS-CoV-2seasonal human coronavirus

Identifiers

PMID34407480
PMCPMC8364517
OpenAlexW3195468479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.